AbCellera Biologics (ABCL) EBIT (2020 - 2026)
AbCellera Biologics (ABCL) reported EBIT of -$57.5 million for Q1 2026, up 8.2% on a YoY basis from -$53.2 million in Q1 2025, and down 101.24% quarter-over-quarter from -$28.6 million in Q4 2025.
AbCellera Biologics (ABCL) EBIT (2020 - 2026) Analysis & Trends
AbCellera Biologics has reported EBIT for 7 years, with the latest figure at -$57.5 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 8.2% year-over-year to -$57.5 million; the trailing twelve-month figure through Mar 2026 stood at -$212.0 million (up 34.28% YoY), and the FY2025 full-year result was -$217.1 million, up 31.03% from the prior year.
- EBIT for Q1 2026 stood at -$57.5 million, down from -$28.6 million in the prior quarter.
- The five-year high for EBIT was $225.0 million in Q1 2022, with the low at -$93.7 million in Q3 2024.
- Historically, EBIT has averaged -$35.9 million across 5 years, with a median of -$54.9 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT jumped 234.31% — and 2023, when it slumped 512.07%.
- AbCellera Biologics' EBIT stood at -$37.8 million in 2022, then slumped by 74.85% to -$66.1 million in 2023, then declined by 10.15% to -$72.8 million in 2024, then soared by 60.71% to -$28.6 million in 2025, then slumped by 101.24% to -$57.5 million in 2026.
- The last three EBIT figures came in at -$57.5 million (Q1 2026), -$28.6 million (Q4 2025), and -$76.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -65.83 Mn |
| 10 | AbCellera Biologics | 1.55 Bn | 1.44 Bn | - | -57.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.52 Mn |
| Dec 31, 2025 | -28.58 Mn |
| Sep 30, 2025 | -76.28 Mn |
| Jun 30, 2025 | -49.59 Mn |
| Mar 31, 2025 | -62.66 Mn |
| Dec 31, 2024 | -72.76 Mn |
| Sep 30, 2024 | -93.66 Mn |
| Jun 30, 2024 | -93.45 Mn |
| Mar 31, 2024 | -54.89 Mn |
| Dec 31, 2023 | -66.05 Mn |
| Sep 30, 2023 | -54.89 Mn |
| Jun 30, 2023 | -51.39 Mn |
| Mar 31, 2023 | -64.87 Mn |
| Dec 31, 2022 | -37.78 Mn |
| Sep 30, 2022 | 37.74 Mn |
| Jun 30, 2022 | -8.40 Mn |
| Mar 31, 2022 | 224.95 Mn |
| Dec 31, 2021 | 81.55 Mn |
| Sep 30, 2021 | -28.10 Mn |
| Jun 30, 2021 | -7.03 Mn |